Related Experiment Videos
Remacemide hydrochloride: a novel antiepileptic agent
1Department of Pharmacology and Therapeutics, University of Wales College of Medicine, Heath Park, Cardiff, UK.
General Pharmacology
|April 1, 1997
Summary
Remacemide hydrochloride demonstrates anticonvulsant and neuroprotective effects, with its metabolite being more potent. Both compounds act by blocking the N-methyl-D-aspartate (NMDA) receptor channel, offering potential epilepsy and ischemia treatments with low toxicity.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Remacemide hydrochloride exhibits anticonvulsant activity in animal models and clinical efficacy for partial seizures.
- Its desglycinated metabolite is a more potent anticonvulsant and N-methyl-D-aspartate (NMDA) receptor antagonist.
Purpose of the Study:
- To investigate the mechanism of action of remacemide hydrochloride and its metabolite.
- To evaluate their anticonvulsant, neuroprotective, and toxicological profiles.
Main Methods:
- Assessing anticonvulsant activity in animal epilepsy models.
- Measuring [3H]MK801 binding displacement and N-methyl-D-aspartate (NMDA)-induced depolarizations.
- Evaluating neuroprotection in cerebral ischemia models and assessing toxicity.
Main Results:
- Remacemide hydrochloride and its metabolite are potent anticonvulsants, with the metabolite being significantly more potent.
- Both compounds block the NMDA receptor channel, suggesting a shared mechanism of action.
- Remacemide hydrochloride displays neuroprotective properties and low toxicity compared to other NMDA antagonists.
Conclusions:
- Remacemide hydrochloride and its metabolite represent promising therapeutic agents for epilepsy due to their NMDA receptor channel blockade.
- The low toxicity profile enhances their potential clinical utility.
- Further research into NMDA receptor modulation is warranted for developing novel antiepileptic and neuroprotective drugs.